QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an ...

A term baby boy presented to our institution with stridor and cyanosis. He was born at 40 weeks gestation at the referring hospital to a 23-year-old primigravida woman by vacuum-assisted vaginal ...

Palvella Therapeutics (NASDAQ:PVLA) is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN ...

Palvella Therapeutics, Inc. ( PVLA) announced that it has completed the rolling submission of its NDA to the U.S. FDA for QTORIN 3.9% rapamycin anhydrous gel. The therapy is being developed for ...

Palvella (PVLA) advances QTORIN rapamycin with Phase 3 SELVA data and a rolling NDA. Read here for a detailed investment ...

(HealthDay News) – Treatment with sildenafil results in regression of lymphatic malformations in children, according to three cases presented in a letter published in the Jan. 26 issue of the New ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Shares of Palvella Therapeutics rose in premarket trading Tuesday after the company reported positive results from its phase 3 trial of its treatment targeting microcystic lymphatic malformations.

Kennedy Hubbard looks different than most 20-somethings. “We’re well aware of how she appears,” Kennedy’s mom, Leanne, said. “It’s human nature to stare. It’s just not something you see all the time.

On Tuesday, Norwegian news site VG reported that a 16-year-old boy found his newest Facebook profile photo deleted automatically by the site, but not for containing offensive content or ...